Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Repligen (RGEN)

Repligen completes BioLife Solutions acquisition; BioLife to be delisted from Nasdaq

Neutral Impact 4 of 5 m&a Written later

Repligen said on October 6, 2026 that it completed its acquisition of BioLife Solutions, under a merger agreement dated July 21, 2026. BioLife shareholders received $11.25 in cash and 0.1442 Repligen common shares for each BioLife share, and BioLife's stock is set to stop trading and be removed from Nasdaq. Repligen has not yet quantified the deal's expected effect on its 2026 outlook and plans to address it on its third quarter 2026 earnings call.

Key points

  • Each BioLife share converted into 0.1442 Repligen common shares plus $11.25 in cash, per the filing.
  • The Mergers closed on October 6, 2026; BioLife notified Nasdaq of the closing that day.
  • BioLife common stock was to be halted after the after-market session on October 5, 2026, and suspended as of the close on October 6, 2026.
  • Repligen will provide details on the transaction's expected impact on its 2026 outlook on its third quarter 2026 earnings call.

The filing

CompanyRepligen (RGEN)
Form8-K, current report
Filed with the SECOct 6, 2026, 9:14 AM ET
Accession number0001193125-26-415015

Items reported: 2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.